Table 2 Outcomes of included studies in the meta-analysis
Reference | POAF | Duration of ICU (hours) | Hospitalization (days) | Mortality | Nonfatal CBV | |||||
|---|---|---|---|---|---|---|---|---|---|---|
NAC | Control | NAC | Control | NAC | Control | NAC | Control | NAC | Control | |
Ozaydin 2008 [12] | 3/58 | 12/57 | NA | NA | 7.7 ± 3 | 7.9 ± 4.2 | 0/58 | 2/57 | 1/58 | 0/57 |
Kazemi 2013 [16] | 14/120 | 19/120 | 120 ± 45.6 | 115.2 ± 79.2 | 7.4 ± 1.3 | 7.2 ± 0.9 | 1/120 | 2/120 | 1/120 | 1/120 |
Eren 2003 [19] | 2/10 | 1/10 | NA | NA | NA | NA | 0/10 | 0/10 | 0/10 | 0/10 |
Orhan 2006 [20] | 0/10 | 1/10 | 23.2 ± 1.75 | 22.6 ± 1.84 | 7.2 ± 0.42 | 7.3 ± 0.48 | 0/10 | 0/10 | NA | NA |
Ozaydin 2013 [21] | 9/104 | 25/104 | NA | NA | NA | NA | 1/104 | 2/104 | 2/104 | 0/104 |
Peker 2008 [22] | 0/19 | 2/21 | NA | NA | NA | NA | 0/19 | 0/21 | 0/19 | 0/21 |
Wijeysundera 2007 [23] | 50/88 | 58/87 | 45.6 | 40.8* | 8 (6–12) | 8 (6–12)†| 0/88 | 7/87 | 4/88 | 4/87 |
EI-Hamamsy 2007 [24] | 4/50 | 6/50 | NA | NA | 5.4 ± 2.3 | 5.3 ± 2.5 | 3/50 | 0/50 | 0/50 | 0/50 |
Haase 2007 [25] | 19/30 | 16/30 | 44 | 45* | 8(7–11) | 8(7–11)†| 0/30 | 1/30 | NA | NA |
Kim 2011 [26] | 4/24 | 8/24 | 72 ± 36 | 81.6 ± 50.4 | 11.3 ± 6.3 | 10.5 ± 4.5 | 0/24 | 2/24 | 0/24 | 0/24 |